| Literature DB >> 30320289 |
Sumit Kumar1, Sourav Taru Saha2, Liang Gu2, Gabriella Palma2, Shanen Perumal2, Ashona Singh-Pillay3, Parvesh Singh3, Amit Anand4, Mandeep Kaur2, Vipan Kumar1.
Abstract
1H-1,2,3-Triazole tethered imidazole-isatin and imidazole-isatin-thiosemicarbazone conjugates were synthesized and evaluated against MCF-7 and MDA-MB-231 cell lines. Antiproliferative activities of the synthesized conjugates revealed an optimum combination of longer alkyl chain length as spacer and a halogen-substituent on the isatin ring as a pre-requisite for good activity. The compound 6g with an optimum combination of chloro-substituent at C-5 position of isatin ring and a butyl chain length proved to be most active and noncytotoxic with IC50s of 54.25 and 26.12 μM against MCF-7 and MDA-MB-231 cell lines, respectively.Entities:
Year: 2018 PMID: 30320289 PMCID: PMC6175498 DOI: 10.1021/acsomega.8b01513
Source DB: PubMed Journal: ACS Omega ISSN: 2470-1343
Scheme 1Synthesis of Substituted N-Alkyl-azido-isatins
Scheme 2Synthesis of 2-Methyl-5-nitroimidazole–Isatin Conjugates and 2-Methyl-5-nitroimidazole–Isatin–Thiosemicarbazones
Figure 1Representative graph comparing the percentage growth inhibition of MCF-7 and MDA-MB 231 cells at selected concentrations of test compounds 6a, 6b, 6c, 6d, 6e, 6f, 6g, 6h, 6i, 6j, 6l, 7a, 7b, 7c, 7d, 7e, 7f, 7g, 6k, 7i, and 7k. Plumbagin (40 μM) was used as a positive control. Data are mean ± standard deviation S.D. (n = 3) from raw data, where *p < 0.05, **p < 0.01 and ***p < 0.001 significant difference to untreated control.
IC50 Values of Synthesized Conjugates against MCF-7 and MDA-MB-231 Cell Lines along with % Yield
Figure 2Representative graph showing percentage growth inhibition of HEK-293 cells at selected concentrations of test compounds 6g, 6h, 6l, and 7d. Plumbagin (40 μM) was used as a positive control. Data are mean ± standard deviation S.D. (n = 3) from raw data, where *p < 0.05, **p < 0.01 and ***p < 0.001 significant difference to untreated control.
IC50 Values of Synthesized Conjugates against HEK-293 Cell Lines
| entry | HEK-293 (μM) |
|---|---|
| >100 | |
| 12.11 | |
| >100 | |
| >100 |
Figure 3Three-dimensional illustration of docked ligands in IGF-1 receptor kinase domain.
Docking of the Most Active Compounds in IGF-1 Receptor
| ligand identifier | docking score/(kcal/mol) | rmsd i.b. | rmsd u.b. |
|---|---|---|---|
| –7.3 | 1.968 | 2.325 | |
| –7.8 | 2.452 | 3.354 | |
| –7.6 | 2.790 | 3.639 | |
| –7.2 | 3.738 | 8.021 | |
| –6.7 | 3.006 | 4.077 | |
| native ligand | –7.2 | 1.721 | 2.587 |
Physical Properties of the Docked Compounds
| pharmacophore
features | |||||||
|---|---|---|---|---|---|---|---|
| compound ID | log | TPSA/Å2 | rotatable bonds | molecular weight/g mol–1 | acceptors | donors | ionizable groups/charge |
| 1.55 | 131.73 | 8 | 443.84 | 7 | 0 | 0 | |
| 1.98 | 131.73 | 9 | 457.87 | 7 | 0 | 0 | |
| 1.77 | 131.73 | 9 | 441.42 | 8 | 0 | 0 | |
| 0.82 | 197.16 | 8 | 454.47 | 7 | 2 | 1/+ | |
| 1.50 | 197.16 | 11 | 496.55 | 7 | 2 | 1/+ | |
| native ligand | –7.21 | 307.09 | 8 | 514.26 | 18 | 11 | 3/– |
Figure 4Generalized SAR of the synthesized compounds against BC.